Skip to headerSkip to main contentSkip to footer
Get our Free E-newslettersGet our Free E-newsletters
Kiplinger logoLink to homepage
Get our Free E-newslettersGet our Free E-newsletters
Subscribe to Kiplinger
Subscribe to Kiplinger
Save up to 76%
Subscribe
Subscribe to Kiplinger
  • Store
  • Home
  • Investing
  • Retirement
  • Taxes
  • Personal Finance
  • Your Business
  • Wealth Creation
    • Podcasts
    • Economic Outlooks
    • Tools
    • Kiplinger's Personal Finance Magazine
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger's Investing for Income
    • Kiplinger's Retirement Report
    • Store
    • Manage My E-Newsletters
    • My Subscriptions
Skip advert
  • Home
  • Kip 25
Kip 25

5 Best Health Care Mutual Funds for the Long Run

These five health care mutual funds offer up a one-two punch of both defensive properties and an ability to run with the bulls.

by: Kent Thune
October 7, 2020
Piggy bank near stethoscope

Getty Images

Skip advert

It's difficult to get the best of both worlds in mutual funds. Some products might be great for opportunistically chasing growth but just as quickly peel back when investors go risk-off, for instance. Others might hold up well in pullbacks but fail to participate in broad-market rips.

Health care funds, however, can exhibit defensive characteristics and deliver market-beating performance over long bull stretches.

The defensive nature of health care stocks comes from the fact that consumers will generally continue to buy these goods and services that they need, no matter what the economy is doing. The long-term growth aspect is supported by the combination of an aging population and advances in medical science and technology.

For evidence of the short- and long-term dual play for health care funds, look no further than the actual numbers. For the year through Oct. 6, 2020 – a decidedly tumultuous period – the average health care mutual fund had outperformed the S&P 500, 10.9% to 5.5%. Over the past decade, meanwhile, health care funds have averaged 15.5% returns annually, which is more than 2 percentage points better than the broader market.

Where can you find this 1-2 sector punch? Read on as we examine five of the best health care mutual funds for the long run.

  • The 25 Best Low-Fee Mutual Funds You Can Buy
Data is as of Oct. 6. Yields represent the trailing 12-month yield, which is a standard measure for equity funds.
Skip advert
Skip advert
Skip advert

1 of 5

Vanguard Health Care Fund Investor

Vanguard logo

Vanguard

Skip advert
  • Assets under management: $48.7 billion
  • Dividend yield: 1.0%
  • Expenses: 0.32%

Let's start with Vanguard Health Care Fund Investor (VGHCX, $218.07), a straightforward but strong choice for investors wanting low expenses, low turnover and below-average risk compared to other health-care funds.

Vanguard Health Care takes a broad approach to health care, investing in various sectors both in the U.S. and abroad. Pharmaceutical stocks make up the biggest chunk of the portfolio at 40% of assets, but VGHCX investors are also exposed to biotech, health care equipment, health insurers and several other industries. Also, a good third of the portfolio is in international stocks.

This blend is well-evidenced in its top 10 holdings, which include the likes of America's UnitedHealth (UNH) and Pfizer (PFE), as well as the U.K.'s AstraZeneca (AZN) and Switzerland's Novartis (NVS).

One caveat for this health care fund is the buy-and-hold approach from Wellington Management, VGHCX's fund advisor. The approach tends to produce average returns compared to its peers. But it does so with a below-average risk profile, and remember: The category average still beats the S&P 500, which is a key goal when you're investing in sector funds.

Consider that VGHCX's 10-year average annual return of 14.9% is about 60 basis points lower than the category average (a basis point is one one-hundredth of a percent). But that's still better than the S&P 500's 13.6% average, and it has come with less volatility.

Learn more about VGHCX at the Vanguard provider site.

  • The Best Vanguard Funds for 401(k) Retirement Savers
Skip advert
Skip advert
Skip advert

2 of 5

Fidelity Select Health Care Portfolio

Fidelity logo

Fidelity

Skip advert
  • Assets under management: $9.2 billion
  • Dividend yield: 0.3%
  • Expenses: 0.70%

Fidelity Select Health Care Portfolio (FSPHX, $32.09) is a slight shift from VGHCX, in that it dials up the risk but also produces better returns.

Fund manager Eddie Yoon has been at the helm of FSPHX since 2008; this tenure gives him complete credit for the outstanding 10-year annualized return of 19.2%. His is a three-part strategy that involves investing a heavy chunk of assets into steadily growing companies, then bolstering growth with biotechs as well as other fast-growing firms.

At the moment, this Kip 25 fund boasts 20%-plus allocations to health care equipment, biotechnology and pharmaceuticals, with another heavy slug (19%) in health insurance. The fund is filled out with life sciences, health-care tech and even software companies. You also get some international diversification at about 20% of assets. UnitedHealth, Switzerland's Roche Holding (RHHBY) and COVID play Regeneron (REGN) are all major players in this portfolio.

You'd think the aggressive stance would put Fidelity Select Health Care investors in considerable risk, but Morningstar says risk is about on par with the category average. That's a great tradeoff considering FSPHX's performance beats at least 80% of health care mutual funds in every significant time frame.

Note: PRHSX's status is "restricted." The fund is open to new investors, but you'll have to buy shares either directly from T. Rowe Price or through financial intermediaries with an existing position.

Learn more about FSPHX at the Fidelity provider site.

  • 15 Best Fidelity Funds for the Next Bull Market
Skip advert
Skip advert
Skip advert

3 of 5

T. Rowe Price Health Sciences

T. Rowe Price logo

Courtesy of T. Rowe Price

Skip advert
  • Assets under management: $15.5 billion
  • Dividend yield: 0.1%
  • Expenses: 0.76%

T. Rowe Price Health Sciences (PRHSX, $94.41) has consistently outperformed its category peers in part because it's not afraid to overweight more aggressive areas of the health care sector.

PRHSX divides the health care sector into five main areas: pharmaceuticals, biotechnology, life sciences, services, and product and device providers. Allocation across these main areas will vary depending upon the potential that management sees with each respective area.

Health Sciences' management has its biggest chunk of assets (35%) dedicated to biotechs – the highest-risk, highest-reward segment of health care. The rest of the portfolio is split into 12%-20% chunks across the other four industries mentioned here. Top holdings are heavy in large caps: UnitedHealth, Intuitive Surgical (ISRG) and Vertex Pharmaceuticals (VRTX) represent some of the health care fund's biggest weights.

PRHSX is a well-above-average fund in most short-term time periods, but it has really shone in the long term. It beats 99% of its peers in the trailing 10- and 15-year periods, with 20.1% and 15.7% average annual returns, respectively.

Note that PRHSX is open to new investors but you'll have to buy shares either directly from T. Rowe Price or through financial intermediaries with an existing funded position.

Learn more about PRHSX at the T. Rowe Price provider site.

  • Best Bond Funds for Every Need
Skip advert
Skip advert
Skip advert

4 of 5

Janus Henderson Global Life Sciences T

Janus Henderson logo

Janus Henderson

Skip advert
  • Assets under management: $4.4 billion
  • Dividend yield: 0.63%
  • Expenses: 0.92%

While Janus Henderson Global Life Sciences T (JAGLX, $67.45) might sound like a fund focused specifically on one corner of the health care sector, it actually provides another means of broad access to several industries.

The JAGLX portfolio consists of companies that the fund management believes can address "unmet medical needs or improving efficiencies." In translation, shareholders of JAGLX get a healthy dose of pharmaceutical companies, biotech firms and medical device companies, including top holdings such as Merck (MRK), AbbVie (ABBV) – both Dividend Aristocrats – and Boston Scientific (BSX).

But biotech is the key to performance here, writes portfolio manager Andy Acker.

"We believe biotech's innovation will only accelerate from here, creating opportunities for investors who can identify the most promising drug developments," he says. "When we look at the Global Life Science Fund's cumulative 10-year return, we see that our positioning in biotechnology has been a key driver of outperformance."

This is a decidedly large-cap fund, with some 40% of the portfolio invested in companies larger than $100 billion. It's also heavily U.S. but with some (20%) international exposure.

From a performance standpoint, JAGLX offers the 1-2 punch that health care mutual fund investors are looking for, with an average risk profile but above-average returns in most time frames.

Learn more about JAGLX at the Janus Henderson provider site.

  • Janus Henderson Global Equity Income (HFQTX) Joins the Kip 25
Skip advert
Skip advert
Skip advert

5 of 5

Fidelity Select Medical Technology and Devices Portfolio

Fidelity logo

Fidelity

Skip advert
  • Assets under management: $7.3 billion
  • Dividend yield: 0.0%
  • Expenses: 0.71%

Fidelity Select Medical Technology and Devices Portfolio (FSMEX, $69.52) isn't a sector fund, but instead an industry fund. In short, it focuses on companies dealing in medical equipment and devices (and related technologies), and doing so has helped it produce category-beating returns for some time.

Specifically, some 60% of the fund's assets is invested in health care equipment firms, while another 19% goes toward life sciences tools and services. The rest of the assets are sprinkled among insurers, health care tech, health care supplies and other industries. Top holdings include the likes of Thermo Fisher Scientific (TMO), Becton Dickinson (BDX) and Danaher (DHR).

This is a considerably more concentrated fund, at 47 holdings versus FSPHX's 88, but it still manages to tamp down risk, which Morningstar calls average.

From a performance standpoint, FSMEX has long been one of the best health care mutual funds you can buy. While Fidelity Select Medical Technology and Devices is better than a respectable 36% of its peers over the 52 weeks, at 32% returns, it's in the 90th percentile for all other longer-term time frames.

Learn more about FSMEX at the Fidelity provider site.

  • 13 Best Vanguard Funds for the Next Bull Market
Kent Thune held PRHSX and VGHCX in some client accounts as of this writing. This article is for information purposes only, thus under no circumstances does this information represent a specific recommendation to buy or sell securities.
Skip advert
Skip advert
Skip advert
  • healthcare stocks
  • mutual funds
  • Kip 25
Share via EmailShare on FacebookShare on TwitterShare on LinkedIn
Skip advert
Skip advert
Skip advert
Skip advert

Recommended

The Best Vanguard Funds for 401(k) Retirement Savers
mutual funds

The Best Vanguard Funds for 401(k) Retirement Savers

Vanguard funds account for roughly a third of the 100 most popular 401(k) retirement products. We rank Vanguard's best actively managed funds, includi…
May 10, 2022
100 Most Popular Mutual Funds in 401(k) Retirement Accounts for 2022
401(k)s

100 Most Popular Mutual Funds in 401(k) Retirement Accounts for 2022

These mutual funds have the most assets under management in 401(k) workplace retirement plans.
May 4, 2022
BlackRock Event Driven Equity Profits from Corporate Change
mutual funds

BlackRock Event Driven Equity Profits from Corporate Change

BALPX capitalizes on mergers, executive turnover and other events.
April 29, 2022
T. Rowe Price Small-Cap Value (PRSVX) Stands Out
Kip 25

T. Rowe Price Small-Cap Value (PRSVX) Stands Out

In this turbulent market, value-priced, higher-quality small caps are holding up better than their fast-growing counterparts.
April 27, 2022

Most Popular

15 Stocks Warren Buffett Is Buying (And 7 He's Selling)
stocks

15 Stocks Warren Buffett Is Buying (And 7 He's Selling)

Berkshire Hathaway CEO Warren Buffett is a bull once more! The Oracle and his team entered eight new positions and added to others in a big way.
May 17, 2022
Your Guide to Roth Conversions
Special Report
Tax Breaks

Your Guide to Roth Conversions

A Kiplinger Special Report
February 25, 2021
Should You Consider a Roth Conversion While the Market is Down?
Roth IRA Conversions

Should You Consider a Roth Conversion While the Market is Down?

Investors who are hurting right now as the stock market takes a hit may want to console themselves with a possible tax bargain created by a Roth conve…
May 16, 2022
  • Customer Service
  • About Us
  • Advertise With Us (PDF)
  • Privacy Policy
  • Cookie Policy
  • Kiplinger Careers
  • Accessibility
  • Privacy Preferences

Subscribe to Kiplinger's Personal Finance

Be a smarter, better informed investor.
Save up to 76%Subscribe to Kiplinger's Personal Finance
Do Not Sell My Information

Kiplinger is part of Future plc, an international media group and leading digital publisher. Visit our corporate site www.futureplc.com
© Future US LLC, 10th floor, 1100 13th Street NW, Washington, DC 20005. All rights reserved.

Follow us on InstagramFollow us on FacebookFollow us on TwitterConnect on LinkedInConnect on YouTube